| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972875 | The Journal of Heart and Lung Transplantation | 2008 | 6 Pages |
Abstract
This pilot study suggests that initiation of concentration-controlled everolimus with a concomitant 25% reduction in CsA dose in maintenance heart transplant patients is associated with no significant decline in renal function, and no indication of increased rejection to Month 3 post-conversion. Evaluation of more substantial CsA dose reductions is required.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Heather MD, Peter MD, Haissam MD, Marcelo MD, Michael MD, Andrew MD, Jonathan MD, Marc PhD, Richard MD, Jeffrey R. MD, CADENCE Study Group CADENCE Study Group,